Per corp presentation
8,900 patients diagnosed annually.
BPDCN 500 - 1000 cases in US annually, of which 60 -70% become relapsed/refactory
so that puts that at 300-700 in US, seeking alpha wild guess was to double that for international markets. See slide 16
For AML, and especially for the combo, I think it is way to early try to even guess at size of market. Still in ph1b/2 right? If a combo turns out to be the MacDaddy of SOC, i would imagine it would be a substantial market opportunity.
for annual cases and deaths:
For treatment success:
Very good response to chemo, it looks like...but I would imagine there is a market for Minimal Residual Disease patients.
For options post chemo: